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Guinea pigs  sensitized with  heterologous renal  cortical tubular basement 
membrane (TBM)  1 preparations develop a  characteristic form of autoimmune 
tubulointerstitial nephritis (anti-TBM disease) (1). Widespread cortical tubular 
damage occurs, together with an extensive interstitial infiltrate that includes 
lymphocytes, plasma cells, macrophages, and multinucleated giant cells (1-5). 
The disease is believed to be mediated by anti-TBM autoantibodies for several 
reasons: linear deposits of immunoglobulin are present along the TBM (1,  3); 
antibodies reactive with normal TBM can be demonstrated in the serum and in 
eluates from diseased kidneys (1,  4,  6,  7),  and the disease can be transferred 
with serum containing anti-TBM antibodies (4-9). 
It  has  not been shown which immunoglobulin type mediates the  disease, 
although IgG has been detected along the TBM (2-9). In the guinea pig there 
are two well characterized isotypes (subclasses) of IgG (IgG1 and IgG2) with 
distinctive  biologic  properties  (10). IgG1 binds  to  basophils  and  mast  cells 
(homocytotropic), mediates anaphylactic reactions (11, 12), and is not hemolytic 
in  the  usual  complement assay,  although  it  does  fix  complement by  the 
alternative pathway (13-17). IgG2 initiates complement-mediated  hemolysis by 
the classical pathway, binds to macrophages (cytophilic), and can mediate the 
hemorrhagic component of Arthus reactions (13-16, 18). However, there is not 
complete agreement on the roles of IgG1 and IgGs in these phenomena (14, 19) 
and little is known of the role of IgG1 and IgG2 in more complicated immunologic 
phenomena, such as  autoimmune diseases  (20). Preliminary data have sug- 
gested that IgG~ may transfer anti-TBM disease (9), but no other information 
is available. 
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We report here studies designed to determine whether IgG~, IgG2, or both, 
can mediate anti-TBM disease.  The experiments employed passive transfer of 
isologous  IgG1 or  IgG2 anti-TBM  antibodies  into  normal  strain  XHI  guinea 
pigs.  Both IgG isotypes effectively initiated the disease.  However, the passive 
transfer of either isotype of autoantibodies stimulated the recipient to produce 
anti-TBM antibodies so that high titers of anti-TBM antibodies of both isotypes 
were present in the circulation.  In this model it appeared that self-tolerance 
was abrogated by isologous autoantibodies. 
Materials  and Methods 
Animals:  Antigen Preparation and Immunization.  Male and female strain XIII guinea pigs 
were used exclusively because they are highly and consistently susceptible to anti-TBM disease 
(4). 
Rabbit TBM was prepared by methods previously described (21).  In brief, cortical tissue from 
fresh  frozen  rabbit  kidneys  (Pel-Freez  Bio-Animals,  Inc.,  Rogers,  Ark.)  was  sieved  to  yield 
fractions containing approximately  90%  tubules.  This tubular fraction was  sonicated,  washed 
repeatedly in phosphate-buffered saline (PBS, 0.15 M NaC1, 0.01 M sodium phosphate pH 7.3), 1 
M  NaC1,  and  distilled  water,  and  lyophilized.  The  TBM  preparation  was  resuspended  by 
sonication in 0.15 M  NaC1 and emulsified with an equal volume of complete Freund's adjuvant 
(CFA,  containing Mycobacterium butyricum;  Difco  Laboratories,  Detroit,  Mich.).  Strain  XIII 
guinea pigs (350-500 g) were injected with 500 /~g of TBM in 0.2 ml of adjuvant, divided equally 
between  the  hind  foot  pads.  Animals  were  exsanguinated  by  cardiac  puncture  under  ether 
anesthesia 14-18 days after immunization,  at a  time when they consistently had severe renal 
disease and high levels of anti-TBM antibodies. The sera were pooled and stored at -20°C until 
used. 
Antibodies to bovine gamma globulin (BGG, fraction II; Miles Laboratories, Inc., Kankakee, 
Ill.) were raised by immunization of strain XIH guinea pigs with 100 gg of BGG emulsified in 0.2 
ml CFA.  On day 14 the animals were boosted intradermally with 100  gg of BGG in saline and 
exsanguinated. 
Separation of IgGl and IgG2 Antibodies.  The IgGl and IgG2 antibodies were separated by a 
slight modification of the method of Oettgen et al.  (22).  All procedures were carried out at 4°C. 
The anti-BGG serum pool contained both homocytotropic and hemolytic antibodies (see below), 
and was added to the anti.TBM serum pool (1:9 parts) to serve as a  marker for the completeness 
of  the  separation  of  IgGt  and  IgG2  fractions.  The  combined  anti-TBM,  anti-BGG pool  was 
processed in six batches of approximately 220 ml.  The globulins were precipitated and washed 
once in 50% saturated ammonium sulphate,  redissolved in 50 ml of 0.005 M  sodium phosphate 
buffer, pH 8.0  (column buffer),  and dialyzed for 48 h  against five changes of 2 liters of column 
buffer. The samples were centrifuged at 10,000g for 30 min and applied to a  100  x  2.5-cm column 
of  diethylaminoethylcellulose  (DEAE,  DE52,  Whatman  Chemicals,  Div.  W.  &  R.  Balston, 
Maidstone, Kent England) previously equilibrated with column buffer. The column was eluted 
with a  linear 0-0.5 M NaC1 gradient in column buffer using a  gradient maker (Ultragrad, LKB 
Instruments, Inc.,  Rockville,  Md.).  The protein content of the eluate was monitored at 280 nm 
with  a  recording  spectrophotometer,  and  the  linearity  of  the  gradient  was  confirmed  by 
osmometry. Portions of alternate fractions were adjusted to isotonicity with 3 M NaC1 or distilled 
H20,  and  were  tested  for  homocytotropic  and  hemolytic  antibodies  reactive  with  BGG  (see 
below).  The  fractions  containing  IgG1  and  IgGz  antibodies  were  concentrated  by  pressure 
ultrafiltration (PM30,  Amicon Corp.  Scientific Sys.  Div.,  Lexington,  Mass.)  and were dialyzed 
for 48  h  against several  changes  of 0.15  M  NaC1.  The protein  content of the  final pools was 
measured spectrophotometrically, using the extinction coefficients reported by Leslie and Cohen 
(23): z280 nm (1%)  =  15.2,  IgG~;  14.7, IgG2. 
Characterization of the IgG~ and IgG2 Preparations.  Anti-TBM antibody titers were measured 
by indirect immunofiuorescence  (4).  Serial twofold dilutions of the antisera were made in PBS 
and 50 ttl of each dilution was placed on a  cryostat section of renal cortex from a  normal strain 
XIII guinea pig. The sections were incubated at room temperature for 30 rain, rinsed four times 
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ries, Inc., Cochranville, Pa.),  which was shown by gel diffusion to be reactive with beth guinea 
pig  IgG,,  and  IgG2.  The  sections  were  washed  four  times  in  PBS,  mounted  in  Elvanol,  and 
examined with a  fluorescence microscope. 
Homocytotropic IgG,  anti-BGG antibodies were measured by passive cutaneous anaphylaxis 
(PCA) (11),  0.1 ml of serial twofold dilutions of antiserum in saline were injected intradermally 
into the shaved, depilated flank of normal strain XIII guinea pigs. 4 h later, 5 mg of BGG and 10 
mg of Evans blue dye in 1 ml saline were given i.v. The diameter of bluing was measured 15 rain 
later. The titer of IgG1 anti-BGG antibodies was recorded as the highest dilution with a  distinct 
area of bluing greater than the normal serum control. The titrations were performed in triplicate 
(three individual animals) with positive (anti-BGG antiserum) and negative (normal guinea pig 
serum, NGPS) controls and the geometric mean titer was recorded. 
Hemolytic IgG2 anti-BGG antibodies were measured by passive tanned erythrocyte hemolysis 
(18).  Washed  sheep  erythrocyte  (SRBC)  were  tanned  and  coated  with  BGG  (5  mg/ml).  The 
antisera were  decomplemented  and  absorbed with washed  SRBC  and serial twofold  dilutions 
were made in 50 ~1 of veronal buffer pH 7.4 in Microtiter U  plates (Cooke Laboratory Products 
Div.,  Dynatech Laboratories  Inc.,  Alexandria,  Va.).  25  /~1 of BGG-coated SRBC  was added to 
each well followed by 25/~1 of 6% NGPS in Veronal buffer as a source of complement. The plates 
were incubated at 37°C for 20 rain and the titer was determined as the highest dilution at which 
hemolysis clearly occurred.  Each  assay  was  carried  out in  duplicate  with  positive  (anti-BGG 
antiserum) and negative (NGPS) controls and an SRBC control using tanned but uncoated SRBC. 
Hemagglutinating anti-BGG antibodies (both IgG, and IgG2) were measured by the technique 
of Onkelinx et al. (24).  BGG (10 mg/ml) was coupled to a 50% suspension of washed SRBC in PBS 
with  0.25  M  glutaraldehyde.  Twofold  dilutions  of  decomplemented  test  sera  absorbed  with 
glutaraldehyde treated SRBC were made in 50 pl of 1% NGPS in PBS in Microtiter U plates. 50 
ftl of a 2%-suspension of BGG-SRBC in 1% NGPS in PBS were added to each well and the plates 
were  incubated  at  37°C  for  1x/2 h  and  then  at  4°C  overnight.  Each  assay  was  performed  in 
duplicate with positive and negative controls including SRBC fixed with glutaraldehyde but not 
coated with BGG. 
Passive Transfer of Anti-TBM Disease.  Antisera or purified fractions were injected i.p.  into 
normal strain XIII guinea pigs weighing 240-300 g; larger volumes (20 or 30 ml) were given as 
divided doses on 2  consecutive days.  14 days later the animals were bled by cardiac puncture, 
sacrificed,  and their kidneys  were  fixed  in  formalin  for light microscopy  and  quick-frozen  in 
liquid nitrogen for immunofluorescence microscopy.  The extent of disease  was  measured by a 
morphometric technique described previously (4). In brief, hematoxylin and eosin-stained sections 
were projected onto plain white paper at a  magnification ofabeut ×30. The area showing disease 
and the total area of renal cortex were traced, cut out, and weighed. The extent of the anti-TBM 
disease was calculated as the percent of cortical involvement as determined by the ratios of the 
weights of the traced areas. 
Direct immunofluorescence of the recipient kidneys was performed as described previously (4) 
using fluorescein-conjugated goat antisera reactive with guinea pig IgG (both IgGt and IgGs), 
C3, fibrinogen, and albumin (Cappel Laboratories Inc.).  The conjugates were specific as judged 
by immunoelectrophoresis. 
Analysis  of Serum  from  Passive  Transfer  Recipients.  Serum  obtained  from  the  passive 
transfer recipients at 14 days was assayed for anti-TBM antibodies by indirect immunofluores- 
cence and for anti-BGG antibodies by passive hemagglutination as described above. In addition, 
a pool of serum was made from each of the passive transfer groups using 1 ml of serum from each 
animal in each group and was separated into IgG, and IgG2 fractions by DEAE chromatography 
as above,  employing a  30  ×  1.25-cm column.  After reconcentration to the original volume and 
dialysis aginst 0.15 M  NaC1, the IgG, and IgG2 fractions were assayed for anti-TBM activity by 
indirect immunofluorescence and for anti-BGG activity by passive hemagglutination. 
The relative amounts of anti-TBM antibody present in the serum were estimated based on the 
anti-TBM titers, using the group that had received 10 ml of IgG, as a reference. The assumption 
was  made that the reciprocal of the titer would  be proportional to the volume of preparation 
injected initially. Thus, the expected ratio of the reciprocal antibody titer of groups receiving 20 
or 30 ml compared to the group receiving 10 ml would be 2:1 and 3:1,  respectively. The observed 
ratio of the reciprocal antibody titers for a group of animals was the ratio of the antibody titer of 
that group to that of the group receiving 10 ml of IgG,. 500 
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FIG.  i.  Typical separation of  IgG1 and IgG2 anti-TBM fractions  by a linear  0-0.5 M  NaCI 
gradient in 0.005 M  phosphate pH 8.0. Alternate  5-ml fractions were assayed for anti- 
BGG, PCA, and hemolytic activity.  PTRC lysis  stands for  passive tanned erythrocyte lysis. 
Results 
Preparation of IgG1 and IgG2 Anti-TBM Antibodies (Table I).  The pooled 
serum  (1,420 ml) obtained from 140 guinea pigs immunized  with rabbit TBM 
had an anti-TBM titer of -  1/1,600.  Isologous anti-BGG antiserum was added, 
10% by volume. This serum pool was fractionated into IgG1 and IgG2 components 
by DEAE chromatography.  The quality of the separation of IgGl and IgG2 was 
assayed by measurement of PCA and hemolytic antibody activity against BGG 
(Fig.  1).  The fractions  in  the IgG2 void peak from the  DEAE  column had no 
detectable  IgG~  by  PCA  tests  in  undiluted  fractions  and  were  pooled  and 
concentrated.  Since the PCA titer of the starting  serum pool was 1/1,600 and 
there  was no  evident  loss  of hemolytic  activity in  the  final  concentrate,  we 
estimate  the  IgG1  contamination  to be  <0.1%  (that  is,  we should be able to 
detect  1  part  in  1,600  in  the  undiluted  fraction).  The  second  major  peak 
contained all the detectable PCA activity. The initial fractions of the peak (up 
to  56  mosmol)  also contained  some hemolytic  antibodies  and  these  were  not 
used further.  The  portions of the peak with PCA activity,  eluted between 56 
and  371  mosmol were without hemolytic activity  (in the undiluted  fractions) 
and were pooled as the IgG~ fraction.  The contamination  of the IgG~ by IgG2 
was  estimated  to  be  less  than  0.1%  (that  is,  we  would  be  able  to  detect 
somewhat more than 1 part in 1,024 based on the original titer), although other 
proteins are undoubtedly present.  Thus,  from the serum of guinea pigs sensi- 
tized with rabbit  TBM,  we were able to isolate anti-TBM  antibodies  in both 
IgG~  and  IgG2  fractions  at  a  titer  of  1/2,800  and  with  <0.1%  reciprocal 
contamination. 
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TABLE  I 
Characterization  of IgGl and IgG2 Anti-TBM Fractions 
Anti-TBM prep-  Volume  Protein  Anti-TBM ti- 
aration  conch,  ter*  PCA$ 
Anti-BGG titers 
Hemaggluti- 
Hemolysis§  nationll 
ml  mg/ml 
Antiserum pool¶  1,311  -  -> 1/1,600  1/1,600  1/1,024  1/2,560 
IgG1 fraction  430  18.0  1/2,800  1/2,800  <1"*  1/1,280 
IgG2 fraction  140  18.4  1/2,800  <1"*  1/1,024  1/2,560 
* Measured by indirec~ immunofluorescence with fluoresceinated antibody reactive to both IgG1 
and IgG~ (see Materials  and Methods). The whole antiserum was positive at 1/1,600 and not 
titered further. 
$ Measured in triplicate by passive cutaneous anaphylaxis. 
§ Measured in duplicate by passive tanned erythrocyte hemolysis. 
II Measured in duplicate by passive erythrocyte hemagglutination. 
¶ This pool consisted of 1,180 ml of serum from strain XIII guinea pigs immunized with rabbit 
TBM plus 131 ml of serum from strain XIII animals immunized with BGG. The IgGl and IgG2 
fractions were derived from this pool by DEAE chromatography. 
** No antibody detected in undiluted samples. 
Fractions (Table II).  In  preliminary  experiments  the  unfractionated  antise- 
rum pool was tested for its ability to transfer anti-TBM disease.  We found that 
20 or 30 ml produced extensive disease, whereas 10 ml had little effect. Normal 
strain  XIII  animals  were  then  given  either  IgG1  or IgG2  fractions from this 
anti-TBM  antibody  pool.  These  fractions  had  similar  anti-TBM  titers  and 
protein content (Table I). The severity of disease was measured at sacrifice 14 
days after transfer. Anti-TBM disease was found in recipients of either IgG1 or 
IgG2 fractions, but was more severe in the latter group. The five recipients of 
20 ml of IgG2 anti-TBM antibodies had uniformly severe disease,  affecting 85- 
92%  of the  cortex.  All  eight  recipients  of 20  ml  of the  IgG~  fraction  also 
developed  anti-TBM  disease,  but  the  extent of the  disease  varied  markedly 
(0.5-49.4%)  and  the  mean  extent  (18.7%)  was  significantly  less  (P  <  0.001) 
than that in the recipients of 20 ml of the IgG2 anti-TBM fraction. Transfer of 
30 ml of the IgG1 fraction produced disease which was also quite variable (11.5- 
98.3%)  but  the  mean  extent  (62.2%)  was  not  significantly  less  than  that  in 
recipients of 20 ml of IgG2. Animals that received 10 ml of IgG~ developed little 
or no disease  (mean extent 1.7%).  A  mixture of 5 ml of IgG~ and 5 ml of IgG2 
anti-TBM antibodies was more effective (mean extent 9.2%), than was 10 ml of 
the IgG1 alone.  The effect of 10 ml of IgG2 was not tested.  Control guinea pigs 
given 30 ml of NGPS and anti-BGG pool had a mean area of cortical abnormal- 
ities of 0.3%, the same as that found in normal guinea pigs (Table II). 
The  histological  features,  while  differing  in  extent,  were  similar  in  all 
recipients with disease  (Fig.  2),  whether they received IgG~ or IgG2 anti-TBM 
antibodies  or whole anti-TBM antiserum,  and were the same  as those  in the 
actively sensitized guinea pigs that were the donors of the anti-TBM antiserum. 
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TABLE II 
Extent of Anti-TBM Disease after Passive Transfer of lgG~ and IgG2 Anti-TBM 
Fractions 
Anti-TBM fraction  Volume  No. of  re- 
transferred*  transferred  cipients 
Extent of diseases 
Mean ± SD  Range 
rnl 
IgGl  10  6  1.7  +  1.3  0.2-4.9 
20  8  18.7 ~- 14.7  0.5-49.4 
30  5  62.2 ± 31.5  11.5-98.3 
IgG2  20  5  88.0 ± 2.6  84.9-91.6 
IgGl + IgG2§  10  6  9.2 ± 11.2  0.8-24.9 
Whole antiserum  10  1  1.2 
20  2  38.5  13.7, 63.3 
30  2  83.1  79.8, 86.3 
NGPS + anti-BGGII  30  8  0.3 ± 0.1¶  0.2-0.5 
Normal controls  0  7  0.3 ± 0.1¶  0.2-0.4 
* The fractions are described in Table I. 
$ The extent of the anti-TBM disease is the percent of cortex affected as determined morphomet- 
rically (See Materials  and Methods). Animals were studied 14 days after passive transfer. 
§ 5 ml of IgG1 plus 5 ml of IgG2 antibodies. 
II Normal strain XIII serum plus anti-BGG serum. 
¶ Although  these  are listed  as "disease",  in fact the abnormal  areas of tubular damage  and 
mononuclear infiltrate  lack multinucleated  cells and no anti-TBM antibody was detected, and 
thus they do not actually represent  areas of "anti-TBM disease". 
infiltrate  with  a  few  plasma  cells  and  numerous  multinucleated  giant  cells 
applied  to  tubules.  The  renal  cortical  tubules  were  extensively  damaged  in 
regions of the infiltrate,  as previously described (3, 5).  By immunofluorescence, 
bright linear staining for IgG was seen along the cortical TBM in all recipients 
of anti-TBM antibodies, even in those with no histologic evidence of disease. In 
animals  with  severe  disease,  the  TBM  staining  was  focally  disrupted.  No 
staining for IgG was found along the  TBM in control or normal guinea pigs. 
Staining for IgG in the glomeruli of experimental animals did not exceed that 
seen  in  controls.  Staining for C3  was seen  along the  TBM,  but  was variable 
and weak and was no greater than in control guinea pigs that received normal 
guinea  pig  serum  and  anti-BGG  serum  or  in  untreated  animals.  Increased 
staining  for fibrinogen was  present  in  patches  of peritubular  distribution  in 
areas of cortical disease but not in nondiseased areas  or in control or normal 
animals.  Staining for albumin did not exceed that seen in control animals. 
Serum Studies  in Recipients of IgG1 and IgG2 Fractions (Table 111).  Anti- 
TBM antibodies were detected in all recipients on day 14 but the titers showed 
considerable  variation;  overall  there  was  a  strong  correlation  between  anti- 
TBM  titers  and  extent  of disease  (r  =  0.703,  P  <  0.001),  regardless  of the 
antibody  fraction  injected  (Table  III,  Fig.  3).  Anti-TBM  titers  <  1/40  were 
associated with only very mild anti-TBM disease (mean extent 1.7%; maximum 
5%).  With increasing anti-TBM titers  the  disease  became progressively more 
extensive  and  a  titer  of 1/1,280  was  associated  with  82.7%  cortical  disease. 
Similarly, within groups of animals given the same antibody dose, there was a 1252  LOSS  OF  SELF-TOLERANCE  INDUCED  BY  AUTOANTIBODIES 
FIG.  2(a and b).  Sections of renal cortex from animals given 30 ml of IgG1  (a) or 20 ml of 
IgG~  (b)  anti-TBM  fractions  14  days  previously.  Each  shows  similar  tubular  damage, 
mononuclear  cell  infiltration,  and  multinucleated  giant  cells  applied  to  the  tubules 
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TABLE III 
Anti-TBM and Anti-BGG Antibody Titers of Passive  Transfer Recipients on Day 14 
Extent of  Anti-TBM titerll  Anti-BGG  Titer~] 
Anti-TBM fraction 
transferred*  anti-TBM  Observed  Expected  Means  Range  Observed  Expected 
disease*  Means  Range  ratio§  ratio§  ratio§  ratio§ 
%  % 
IgG~, 10 rnl  1.7  1/40  1/40  (1)  (1)  1/267  1/160-  (1)  (I) 
1/640 
IgG~, 20 ml  18.7  1/132  1/120-  3.3  2  1/400  1/320-  1.5  2 
1/320  1/640 
IgG~, 30 ml  62.2  1/704  1/320-  17.6  3  1/896  1/640-  3.4  3 
1/1,280  1/1,280 
IgG2, 20 rnl  88.0  1/960  1/320-  24.0  2  1/896  1/640-  1.7"*  2 
1/1,280  1/1,280 
IgG,, 5 ml + IgG2, 5  9.2  1/98  1/10-  2.5  1  1/187  1/160-  0.7  1 
ml  1/320  1/320 
NGPS +  anti-BGG  0.3  1  1  -  -  1/960  1/640-  3.0  3 
1/1,280 
* From Table II. 
$ Geometric mean titer. 
§ Expected  and observed ratio of titers to that of IgG, 10 ml group (see Materials and Methods). 
[I Indirect immunofluoreseence. 
¶ Passive hemagglutination. 
** Corrected  for the twofold higher starting titer in the IgG2 fraction (see Table I). 
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FIG.  3.  Extent  of  cortical  disease  found  in  animals  with  different  anti-TBM  titers 
measured  14  days after  transfer  of IgG1,  IgG2,  or a  combination  in  all  doses employed. 
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TABLE  IV 
Relationship between the Extent of Disease and Anti-TBM Titers in Individual 
Animals of Two Groups with Variable Disease 
Anti-TBM  fraction  Extent of  dis- 
Animal  Anti-TBM titer$  Anti-BGG titer$ 
transferred  ease* 
IgGl, 20 ml 
% 
71  0.5  1/20  1/320 
33  6.6  1/80  1/640 
35  11.4  1/160  1/320 
72  17.0  1/160  1/320 
70  21.5  1/80  1/640 
63  21.6  1/320  1/320 
32  21.6  1/80  1/320 
31  49.4  1/160  1/320 
IgG1, 5 ml  +  IgG2, 
5 ml 
56  0.8  1/40  1/320 
37  0.9  1/20  1/160 
55  1.5  1/40  1/160 
57  4.9  1/10  1/160 
39  21.9  1/160  1/160 
38  24.9  1/320  1/160 
* As in Table II. 
As in Table III. 
close relationship between the anti-TBM titer and the extent of the anti-TBM 
disease (Table IV). 
The  wide variation  in  both the  extent of the  anti-TBM  disease  (0.2-98.3%) 
and the titers of anti-TBM antibodies  (1/20-1,280)  in the recipients was unex- 
pected from the  threefold range  of IgG1  and  IgG2  fractions  given  (10-30  ml). 
One possible explanation  was that some of the recipients had been stimulated 
to produce their own anti-TBM antibodies. To evaluate this possibility, we first 
compared the observed and expected ratios of anti-TBM and anti-BGG antibody 
titers  (see Materials  and  Methods).  The  animals  that  received 30 ml  of IgG1 
had a  (geometric) mean anti-TBM antibody titer of 1/704, which was 17.6 times 
greater than the anti-TBM titer of the IgG1 10 ml group (1/40),  despite the fact 
that  they had  received only 3 times  as  many  anti-TBM  antibodies  initially. 
Similarly,  all  the  other  groups  that  had  anti-TBM  disease  also had  greater 
than  the  expected  titer  of anti-TBM  antibodies  (Table  III).  In  contrast,  the 
mean  anti-BGG  hemagglutination  titers  corresponded  closely  with  the  ex- 
pected titers calculated in the same way. 
Active Production  of IgG~ and IgG2 Anti-TBM Antibodies  by Recipients  of 
Isologous Anti-TBM Antibodies.  We sought more definitive evidence for the 
active production of anti-TBM antibodies in the recipients  by analyzing their 
sera for IgG~  and  IgG2  anti-TBM  antibodies.  Pools of sera  from each  group, 
obtained  14 days after passive transfer  of anti-TBM  (and anti-BGG)  antibody 
fractions,  were  separated  on  DEAE  into  IgG~  and  IgG2  fractions  (Table  V). 
Anti-BGG antibodies were present  in  the peak of the  same IgG isotype that 
was transferred at mean titers of 1/80-1/160, but no antibodies could be detected 
in  the  peak  that  contained  the  nontransferred  isotype  even  in  undiluted 
samples.  Thus,  the  anti-BGG  antibodies  were  separated  into  appropriate C.  L.  HALL,  R.  B.  COLVIN,  K.  CAREY,  AND  R.  T.  McCLUSKEY  1255 
TABLE  V 
IgG~ and IgG2 Antibodies in Recipients of lgGl or IgG2 Anti-TBM Fractions: Evidence for an 
Active Autoimmune Response 
Extent 
Anti-TBM fraction 
of dis- 
transferred* 
eases 
Anti-TBM titers§  Anti-BGG titerll 
Serums  IgG~  IgG2  Serums  IgGl  IgG2 
IgG,, i0 ml  1.7  1/40  1/20  <i¶  1/267  1/80  <i 
IgG,,  20 ml  18.7  1/132  1/320  1/40  1/400  1/160  <I 
IgG,,  30 ml  62.2  1/704  1/640  1/640  1/896  1/160  <1 
IgG~,  20 ml  88.0  1/960  1/1,280  1/320  1/896  <1  1/160 
IgG,, 5 ml + IgG2,  9.2  1/98  1/20  1/10  1/187  1/80  1/80 
5 ml 
NGPS  +  anti-BGG  0.3  <1  <1  <1  1/960  1/640  1/640 
serum 
* Same animals as Tables II and III. 1 ml of serum from each animal in a group was pooled and 
separated into  IgG1 and IgG2 antibodies  by DEAE  chromatography. The peaks containing IgG1 and 
IgG2 were reconcentrated to the original  serum volume and assayed for anti-TBM and anti-BGG 
antibodies  (see  Materials and Methods). 
$ From Table II. 
§ Indirect  immunofluorescence. 
II  As in  Table III,  passive hemagglutination. 
¶ No antibody detected  in undiluted samples. 
TABLE  VI 
IgGs Anti-TBM Response in Individual Animals Measured 14 Days after Passive 
Transfer of IgG1 Anti-TBM Antibodies 
Animal* 
Extent of  Anti.TBM titerS  Anti-BGG titerS 
anti-TBM 
disease  Serum  IgG1  IgG2  Serum  IgG~  IgG2 
% 
71  0.5  1/20  1/40  <1  1/320  1/160  <1 
35  11.9  1/160  1/80  1/20  1/320  1/80  <1 
63  21.6  1/320  1/160  1/80  1/320  1/160  <1 
31  49.4  1/160  1/80  1/20  1/320  1/80  <1 
* As in  Table IV. These animals received  20 ml of  IgG1 anti-TBM fraction. 
$ As in Table III. 
fractions after 2 wk in vivo.  Similarly, we found anti-TBM antibodies in the 
IgG1 fraction in all groups that had received the IgG1 fraction, and IgG2 anti- 
TBM  in those  that received IgG2  anti-TBM  antibodies.  The  anti-TBM were 
high, up to 1/1,280, just as they had been in whole serum. 
Furthermore,  in  some  groups  anti-TBM antibodies of the  IgG isotype not 
transferred were also present in high titers. This was seen in those groups that 
developed extensive anti-TBM disease (those that received 20 or 30 ml of IgG1 
or 20 ml of IgG2).  The titers of the nontransferred isotype were as high as  1/ 
1,280  and  in the two  groups with the  most severe disease  were  equal to  or 
greater  than  the  titers  of the  isotype  actually transferred.  Four  sera  from 
animals that received 20 ml of IgG1 were fractionated on DEAE  individually 
(Table  VI).  IgG2  anti-TBM was detected in all three animals that developed 
extensive anti-TBM disease, but was not detected in the animal (71) that did 1256  LOSS  OF  SELF-TOLERANCE  INDUCED  BY  AUTOANTIBODIES 
not develop disease. One animal was sacrificed only 24 h after receiving 8 ml of 
the  IgG1  anti-TBM  fraction.  IgG1  (1/160)  but  no  IgG~  (<1)  anti-TBM  was 
detectable in the fractionated serum. 
Discussion 
We have shown here that strain  XIII guinea pigs immunized with heterolo- 
gous TBM preparations  in adjuvant produce anti-TBM  antibodies of both the 
IgG~  and  IgG2  isotypes,  and  that  transfer  of sufficient  quantities  of either 
isotype to normal  syngeneic recipients results in typical anti-TBM disease,  as 
seen at sacrifice on day 14. The preparations  of IgG~ and IgG2 antibodies used 
had a  high degree of purity. To provide a  monitor for the degree of separation, 
isologous anti-BGG serum was added  (in a  ratio of 1:10) to the unfractionated 
pool  of  anti-TBM  antiserum  and  the  biologic  properties  of  the  anti-BGG 
antibodies were assayed in the IgG1 and IgG= fractions. As judged by PCA and 
hemolytic antibody activity there was less than 0.1% reciprocal contamination. 
Although this represents a high degree of functional purity, other nonimmunog- 
]obulin proteins are undoubtedly presented in these fractions but are unlikely 
to  be  relevant  to  these  experiments.  However,  the  possibility  that  other 
immunoglobulins  participate  in the production of the renal damage cannot be 
excluded at present. 
Analysis of the titers and IgG isotypes in the recipient sera at day 14 led to 
the  unanticipated  conclusions  that  the  recipients  had  been  stimulated  to 
produce their own anti-TBM antibodies and that these autoantibodies partici- 
pated in the production of the renal  damage.  The following lines  of evidence 
support these interpretations:  although each recipient was given approximately 
equal amounts of anti-TBM antibodies,  there was wide variation in the titers 
of anti-TBM  antibodies  in the recipients'  sera;  in the groups of animals  with 
most  severe  disease,  the  titers  were  17-24  times  higher  than  in  those  with 
milder  disease  (which  had  been  given  one-half to  one-third  the  amount  of 
antibody);  the  most  conclusive  evidence  was  that  recipients  with  auti-TBM 
disease  showed  appreciable  titers  of anti-TBM  antibodies  of the  IgG isotype 
that  had  not  been  transferred  (as  well  as  higher  than  expected  titers  of 
antibodies of the isotype that had been transferred).  In contrast,  the simulta- 
neously  administered  anti-BGG  antibodies  were  detected  only  in  the  IgG 
isotype fraction that  had been transferred.  As a  further control,  serum taken 
24 h after administration  of IgG1 antibodies, before an immune response would 
be expected, contained IgGl but no detectable IgG2 anti-TBM antibodies. 
The  discovery  of anti-TBM  antibodies  of the  isotype  that  had  not  been 
transferred  in the recipients sera provides the most incontestable evidence for 
the  production  of autoantibodies  by the  host.  However,  in  view of the  high 
titers  of both types of anti-TBM  antibodies  in  some recipients  at  14 days,  it 
seems almost certain that either IgG1 or IgG2 stimulated the production of both 
IgG  isotypes.  Our  findings  suggest,  but  do  not  prove,  that  IgG2  is  more 
effective in initiating  this autoimmune disease than is IgG1. 
The renal immunofluorescence and histologic findings were similar in recipi- 
ents  of either  IgG~ or IgG2 anti-TBM  antibodies,  and  were indistinguishable 
(qualitatively) from those seen in guinea pigs actively immunized with heterol- 
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antisera  have shown that typical renal lesions can develop as early as 3 days 
(5,  6);  in  this  circumstance  the  initial  renal  damage  is  almost  certainly 
mediated by the transferred antibodies, because an appreciable active immune 
response,  either  humoral  or  cell-mediated,  would  be  unlikely  to  occur  so 
rapidly.  Although  our  data  show  that  either  IgG1  or  IgG2  can  effectively 
initiate anti-TBM disease, the results do not provide an answer to our original 
question as to which isotype actually mediates the renal damage,  since both 
IgG1  and  IgG2 anti-TBM  antibodies  were found in recipients  with  anti-TBM 
disease. 
We can only speculate about the mechanisms by which passively transferred 
autoantibodies initiate autoantibody formation.  The possibilities include modi- 
fication of TBM constituents,  produced either as a  direct result of combination 
with  antibody  or through  secondary pathogenetic  mechanisms,  liberation  of 
sequestered basement membrane antigens, or inactivation or bypass of immune 
mechanisms that normally  hold the autoimmune  response in check.  It seems 
unlikely that complement fixation in the TBM is necessary for the initiation of 
the autoimmune  response,  since no increased  C3 deposition was found in the 
recipients' kidneys. In man,  anti-TBM antibodies have been observed in a  few 
patients with methicillin-induced  interstitial  nephritis  (25).  In such cases it is 
postulated  that  the  autoantibodies  are  formed  as  the  result  of  basement 
membrane  damage that  results  in the exposure or release of basement mem- 
brane  antigens  or by the  formation  of neoantigens  through  the binding  of a 
haptenic  group,  such  as  the  penicilloyl  group  to  the  basement  membrane. 
Other examples of anti-TBM formation in man have followed renal damage of 
various types  (2)  such  as immune  complex glomerulonephritis  (26),  allograft 
rejection (27). Toxic damage with mercuric chloride in rats also results in anti- 
TBM antibody production (28). 
The present observations may provide explanations for certain findings made 
in  previous  experiments  on  anti-TBM  disease  in  the  guinea  pig.  Strain  II 
guinea pigs do not produce anti-TBM antibodies or develop anti-TBM disease 
nearly  as readily  as  strain  XIII guinea  pigs  after  immunization  with  rabbit 
TBM  (4,  29).  The  difference  in  anti-TBM  response  is  controlled  by immune 
response genes (30,  31) linked to the major histocompatibility locus (29).  Even 
after transfer of anti-TBM antibodies,  strain II animals failed to develop anti- 
TBM disease,  although  antibodies were shown to be fixed along the TBM.  In 
contrast,  strain XIII recipients given the same amount of anti-TBM antibodies 
developed  severe  disease  (4).  It  was  hypothesized  that  an  additional  active 
recipient response of unknown nature  (possibly cell-mediated reactivity to the 
TBM) was needed before passive antibody could induce the disease,  and that 
this active response was lacking in strain H guinea pigs. We now suggest that 
this response is the production of anti-TBM antibodies by the recipient.  Thus, 
it is not necessary to invoke the direct participation  of sensitized  cells in the 
production  of renal  damage,  although  helper  T  cells  may  be  required  for 
autoantibody formation.  Our  findings  may also explain  the observation that 
whole  body irradiation  can  prevent  anti-TBM  disease,  unless  the  animal  is 
repopulated with normal bone marrow cells (7, 8). We suggest that irradiation 
might  act,  in  part,  by  depleting  the  animal  of  radiosensitive  circulating 
lymphocytes that are essential for autoantibody formation,  rather than simply 1258  LOSS  OF  SELF-TOLERANCE  INDUCED  BY  AUTOANTIBODIES 
by eliminating  nonspecific cells that participate  in the inflammatory reaction 
in the kidney. 
It is not clear whether the stimulation  of autoantibodies  by autoantibodies 
(which for brevity we term ~'autoimmune  amplification")  is an unusual  event 
or whether in many situations where this phenomenon occurs it goes unnoticed 
because  its  detection  is  difficult  or  impossible.  However,  at  least  one  well- 
documented  example  has  been  reported.  Autoantibody  production  has  been 
demonstrated  during  experimental  isoimmune  hemolytic  anemia  in  human 
volunteers (32). 70 days after the infusion of serum containing anti-CD antibod- 
ies  into  a  normal  subject of the  cDE/cE  rhesus  genotype,  anti-E  antibodies 
developed  in  the  recipient.  It  was  concluded  that  the  binding  of anti-CD 
antibodies  to  the  red cells  resulted  in  a  stimulus  to  the  formation  of anti-E 
autoantibodies. 
Another possible analogy is in experimental thyroiditis which can be trans- 
ferred by isologous murine  antisera  to thyroglobulin.  An early and a  late  (20 
day) phase of cellular infiltration was observed and was postulated to be due to 
an active phase  (33).  However, no antibody production by the recipients  was 
evident,  as  judged  by  the  anti-thyroglobulin  titers.  Although  it  has  been 
suggested that autoantibodies are produced and play a role in the second phase 
of nephrotoxic  serum  nephritis  (34),  there  is  strong  evidence  against  this 
possibility (35). 
It is difficult, if not impossible, to determine whether analogous autoimmune 
amplification  occurs  during  the  course  of autoimmune  diseases  in  man.  In 
some instances, the disease is self-limited, and either autoimmune amplification 
does not develop or in time can be inactivated.  We suggest, however, that this 
phenomenon may serve as a mechanism for the intensification and prolongation 
of some autoimmune diseases, a process that might be interrupted by procedures 
that cause depletion of autoantibodies, such as plasmapheresis  (36). 
Summary 
Initiation of an autoimmune tubulointerstitial disease was achieved in strain 
XIII guinea pigs by passive transfer of functionally pure IgG1 or IgG2 fractions 
of isologous anti-tubular basement membrane  (TBM) serum.  IgG2 appeared to 
be somewhat more effective than IgG,  The immunopathologic features in the 
IgG~ and  IgG2  recipients  were similar  at  the time  of sacrifice,  14  days aider 
transfer.  The recipients that developed disease had higher than expected anti- 
TBM titers  at  14  days.  Furthermore,  anti-TBM  antibodies  were of both  IgG 
isotypes.  In  contrast,  simultaneously  administered  IgG~  or  IgG2  anti-BGG 
antibodies  declined  in  titer  in  the  recipients  and  were  never  found  in  the 
isotype fraction that had not been transferred.  These findings indicate that the 
recipients of anti-TBM antibodies of either IgG~ or IgG2 isotype were stimulated 
to produce anti-TBM autoantibodies, which participated in the pathogenesis of 
the renal disease.  The model demonstrates that autoantibodies may provide a 
mechanism (autoimmune amplification) for the intensification and perpetuation 
of antibody-mediated autoimmune diseases. 
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